Patient-Focused Treatment Decisions in the Management of Multiple Sclerosis

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2021 Fall Managed Care Forum.
If you participated in the live session, you are not eligible for continuing
education credits from this archive.

This activity is valid from January 1, 2022, to March 1, 2023.
 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
Novartis Pharmaceuticals Corporation and Sanofi Genzyme

Description:
Multiple Sclerosis (MS) is a chronic progressive disease. It is the most common neurological cause of disability among young adults, with a prevalence of approximately 1 million cases throughout the United States, and every week around 200 people are diagnosed with the disease. Although there is still no cure for MS, many advances in MS treatment have arrived in recent years, allowing patients to manage these symptoms and improve their quality of life. A number of factors must be considered when selecting a treatment regimen for patients with MS, including variations in clinical and MRI evidence of disease. Over the past decade, there have been numerous revisions to MS diagnostic criteria and the development of multiple new and emerging therapies. While the explosion of these emerging therapies have shown the ability to improve outcomes and quality of life in patient's MS, it makes staying current with best practices a challenge that must be overcome through education.

Upon completion of this activity, participants will be able to:

  • Identify key indicators of multiple sclerosis (MS) to improve early diagnosis and initiation of treatment for MS

  • Explore recent clinical data on the efficacy, safety, and dosing/administration of current and emerging MS therapies and their effect on staging and sequencing

  • Compare and contrast anti-CD20 monoclonal antibodies available for the treatment of relapsing forms of MS

  • Evaluate recent clinical data on S1P therapies for the treatment of relapsing and progressive forms MS

  • Examine the evolving role of BTK inhibitors in the management of relapsing MS patients with highly active disease

  • Outline the recommendations from various MS organizations and societies, comparing the recommendations on the use of DMTs in patients with MS during this COVID-19 pandemic and during COVID-19 vaccine administration

     

Faculty: Carrie M. Hersh, DO, MSc, FAAN
Staff Neurologist, Assistant Professor of Neurology
Cleveland Clinic, Lou Ruvo Center for Brain Health

Disclosure:

Dr. Hersh has served as a consultant for Biogen, Bristol-Myers Squibb, EMD Serono, Genentech, Genzyme, and Novartis. She has received grant/research support from Genentech and Novartis. She serves as a speaker for Biogen, Bristol-Myers Squibb, EMD Serono, Genentech, Genzyme, and Novartis. She has served on an advisory board for EMD-Serono, Genentech, Novartis, and TG Therapeutics. Her presentation has been peer reviewed for any bias.
Planning Committee: Bill Williams, MD has no financial relationships with ineligible companies to disclose.
Jeremy Williams has no financial relationships with ineligible companies to disclose.
Jacqueline Cole, RN, MS, CMCN has no financial relationships with ineligible companies to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
Novartis Pharmaceuticals Corporation and Sanofi Genzyme

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue